CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
Bicalutamidedrug
Likely dose
Bicalutamide 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01044706
NCT01044706Phase 1Completed
CompareCT.gov

Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex® 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Kremers Urban Development Company·interventional·Posted Jan 8, 2010·Updated Mar 2, 2010

In Brief

A Phase 1 clinical trial evaluating Bicalutamide for Healthy. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablet (test) versus Casodex® (reference), administered as 1 x 50 mg tablet under fed conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsWatson Pharmaceuticals

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 8, 2010
Enrollment StartMay 1, 2005
Primary CompletionJul 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 16.5 years ago

Interventions

Bicalutamidedrug

50 mg Oral Tablet